Evigrade
Moderate

Amiodarone × duloxetine

Class III antiarrhythmics (Vaughan Williams)×SNRI

Mechanism

Duloxetine is a CYP1A2 and CYP2D6 substrate. Amiodarone weakly inhibits CYP1A2 — duloxetine levels can rise. There is also an additive QT effect at high duloxetine doses (over 60 mg/day).

Symptoms

QT prolongation on ECG. Dizziness, syncope, palpitations. Rarely: polymorphic ventricular tachycardia (torsades de pointes). Risk is higher with hypokalaemia, hypomagnesaemia, bradycardia, and ischaemic heart disease. On high-dose duloxetine: nausea, insomnia, dry mouth, elevated blood pressure.

Management

On starting the combination, begin duloxetine at 30 mg/day. Check ECG at 1 and 2 weeks. In hypertension and tachycardia, do not exceed 60 mg/day. Antidepressant alternative without CYP1A2 or QT effect: sertraline.

Check the full regimen, not just this pair

Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.

Open checker

Sources

All interactions